Huang, Yunjie published the artcileElexacaftor/tezacaftor/ivacaftor improved clinical outcomes in a patient with N1303K-CFTR based on in vitro experimental evidence, Synthetic Route of 307510-92-5, the publication is American Journal of Respiratory and Critical Care Medicine (2021), 204(10), 1231-1235, database is CAplus and MEDLINE.
Our study showed that treatment with ETI partially restored N1303K-CFTR expression and increased its function to nearly 40% of the wild-type level (Figure 1). Importantly, we have demonstrated clin. benefit of ETI in a child with N1303K (Figure 2), although the clin. response is slow and modest. Possibly, our patient’s second CFTR allele, E193X, and other genetic and nongenetic factors may contribute to this slow improvement as well.
American Journal of Respiratory and Critical Care Medicine published new progress about 307510-92-5. 307510-92-5 belongs to thiazolidine, auxiliary class Membrane Transporter/Ion Channel,CFTR, name is 4-((4-Oxo-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-5-ylidene)methyl)benzoic acid, and the molecular formula is C18H10F3NO3S2, Synthetic Route of 307510-92-5.
Referemce:
https://en.wikipedia.org/wiki/Thiazolidine,
Thiazolidine – ScienceDirect.com